Market Eyes LiveBeam Therapeutics Inc. (BEAM) Stock Rating & Analysis
MELANY's data-driven read on Beam Therapeutics Inc. · Biological Products, (No Diagnostic Substances).
Beam Therapeutics Inc is a biotechnology company developing a new class of precision genetic medicines built on its proprietary base editing technology, aiming to deliver lifelong cures for patients with serious diseases.
Why BEAM scores 55/100
MELANY scores Beam Therapeutics Inc. 55/100 by weighing eight factors. Here is how BEAM breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +29%
What Wall Street price targets and revisions are signalling.
- Analyst targets 90% upside
- Institutional net buying +13.6%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for BEAM
- Operating margin -25827%, cash-burn business, dependent on capital markets
- Short interest 35% of float, high volatility risk on news
- High beta 2.2, amplifies market drawdowns 1.8x+ in selloffs
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Beam Therapeutics Inc. sits in the Healthcare sector theme, which MELANY currently rates 20/100 for strength. Theme strength feeds BEAM's momentum and catalyst factors above.
BEAM trade plan (members only)
MELANY has a full position plan for Beam Therapeutics Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates BEAM
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Beam Therapeutics Inc.'s 55/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BEAM
Is Beam Therapeutics Inc. (BEAM) a buy?
As of 2026-08-05, MELANY rated Beam Therapeutics Inc. Promising with a composite score of 55/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Beam Therapeutics Inc.'s MELANY score?
Beam Therapeutics Inc. (BEAM) has a MELANY composite score of 55/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the BEAM stock rating calculated?
MELANY scores BEAM from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Beam Therapeutics Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Beam Therapeutics Inc. (BEAM) Promising with a composite of 55/100 as of 2026-08-05. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BEAM stock price forecast?
MELANY does not publish price targets or forecasts for BEAM. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 55/100 across eight factors for Beam Therapeutics Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BEAM stock overvalued or undervalued?
MELANY's valuation factor currently reads 98/100 for Beam Therapeutics Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BEAM's read.
What price should I buy BEAM at?
Rather than chasing the current price, MELANY computes a smart entry zone for BEAM: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying BEAM stock?
The top risks MELANY currently flags for Beam Therapeutics Inc.: Operating margin -25827%, cash-burn business, dependent on capital markets; Short interest 35% of float, high volatility risk on news; High beta 2.2, amplifies market drawdowns 1.8x+ in selloffs; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Beam Therapeutics Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 23/100 for Beam Therapeutics Inc., and earnings track record, at 94/100. The 55/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BEAM stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 54/100 for BEAM right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BEAM rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-05. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BEAM continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
BEAM's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.